In the second reprise of our Complimentary Exclusive Video Interview, we had the pleasure to speak with Nick Kadysh, the Founding CEO and President of PharmAla Biotech. Our complimentary exclusive video interview is an initiative to voice the global biopharma leaders by offering them a platform to shed light on the developments in the healthcare…
In an interview with PharmaShots, Robert Barrow, CEO at MindMed shared his views on the Study Acute Effects of Lysergic Acid Diethylamide vs. Psilocybin in Healthy Subjects
Shots:
Robert spoke about the data from the peer-reviewed publication of a study comparing the acute effects of LSD and psilocybin in healthy subjects
Robert also emphasized the clinical results and significance of…
Biosimilars are going in market with vast emerging needs of people for multiple diseases. The biologics that are too costly to be used in the markets. Hence physicians are developing biosimilars a reference product to biologics which are biologically similar to biologics. Our team at PharmaShots have summarized some of the news regarding biosimilars in…
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drugs as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available therapies…

